SCHEMBL2080588

SCHEMBL2080588

COC(=O)/C(=C\c1ccc(Cl)cc1Cl)c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 4/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.42
LMNA P02545 1/20 0.41
RAB9A P51151 4/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TP53 P04637 2/20 0.40
POLB P06746 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12784706 1.00 GABRA1 (0.44) GABRA1GABRG2GABRB3SMN1; SMN2KDM4E
SCHEMBL2080589 1.00 GABRA1 (0.44) GABRA1GABRG2GABRB3SMN1; SMN2KDM4E
SCHEMBL9226532 0.92 LMNA (0.51) GABRA1GABRG2GABRB3SMN1; SMN2KDM4E
SCHEMBL6025838 0.83 GABRA1 (0.51) GABRA1GABRG2GABRB3SMN1; SMN2KDM4E
SCHEMBL6808290 0.83 GABRA1 (0.51) GABRA1GABRG2GABRB3SMN1; SMN2KDM4E
SCHEMBL4460122 0.78 GABRA1 (0.49) GABRA1GABRG2GABRB3SMN1; SMN2KDM4E
SCHEMBL4460115 0.78 GABRA1 (0.49) GABRA1GABRG2GABRB3SMN1; SMN2KDM4E
SCHEMBL9335995 0.76 SMN1; SMN2 (0.49) SMN1; SMN2KDM4EL3MBTL1TDP1MEN1
SCHEMBL11431971 0.76 SMN1; SMN2 (0.49) SMN1; SMN2KDM4EL3MBTL1TDP1MEN1
SCHEMBL9335996 0.76 SMN1; SMN2 (0.49) SMN1; SMN2KDM4EL3MBTL1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897601-B2 Cannabinoid receptor modulators INTERVET, INC. (US) 2011-03-01 US disclosed
EP-1973877-A2 CANNIBINOID RECEPTOR MODULATORS SCHERING CORPORATION (US) 2008-10-01 EP disclosed
US-20070197628-A1 Cannabinoid receptor modulators INTERVET INTERNATIONAL B.V. (NL) 2007-08-23 US disclosed
WO-2007084450-A2 CANNIBINOID RECEPTOR MODULATORS SCHERING CORPORATION (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197628-A1 Cannabinoid receptor modulators CNR1, CNR2, GPR18 GABRA1 86/4885GABRG2 229/4885GABRB3 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.